Risperidone in the Treatment of Children and Adolescents With Autistic Disorder: A Double-Blind, Placebo-Controlled Study of Efficacy and Safety, Followed by an Open-Label Extension Study of Safety.

Trial Profile

Risperidone in the Treatment of Children and Adolescents With Autistic Disorder: A Double-Blind, Placebo-Controlled Study of Efficacy and Safety, Followed by an Open-Label Extension Study of Safety.

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Jun 2014

At a glance

  • Drugs Risperidone (Primary)
  • Indications Autistic disorder
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 12 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Oct 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 02 Sep 2009 Planned end date changed from 1 Sep 2009 to 1 Aug 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top